gsk4382276a
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 9, 2022 (NCT05446740)
Timeline
Indications
Studied for
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06431607 | Phase 2 | May 23, 2024 | GlaxoSmithKline |
| NCT05823974 | Phase 1/Phase 2 (Phase 2) | Apr 27, 2023 | CureVac AG, GlaxoSmithKline |
| NCT05446740 | Phase 1 | Aug 9, 2022 | CureVac AG, GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2022 |
| CureVac AG | For profit | 2 | 0 | 2 | 2022 |
2 organizations
Page 1 / 1